Relmada Therapeutics (RLMD) Short term Debt (2014 - 2018)
Relmada Therapeutics (RLMD) reported Short term Debt of $4.5 million for Q3 2018, up 79.24% year-over-year from $2.5 million in Q3 2017, and up 7.59% on a QoQ basis from $4.2 million in Q2 2018.
Relmada Therapeutics (RLMD) has 5 years of Short term Debt data on file, last reported at $4.5 million in Q3 2018.
- Quarterly Short term Debt rose 79.24% year-over-year to $4.5 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $4.5 million (up 79.24% YoY) and the FY2018 annual result came in at $4.2 million, up 2285.31% from the prior year.
- Short term Debt grew to $4.5 million in Q3 2018 per RLMD's latest filing, from $4.2 million in the prior quarter.
- Across five years, Short term Debt topped out at $46.8 million in Q3 2014 and bottomed at $175853.0 in Q2 2017.
- The 5-year median for Short term Debt is $3.8 million (2017), against an average of $9.2 million.
- The widest annual swing landed in 2016, when Short term Debt tumbled 97.49%; it then jumped 2285.31% in 2018.
- Tracing RLMD's Short term Debt over 5 years: stood at $26.6 million in 2014, then sank by 94.56% to $1.4 million in 2015, then tumbled by 63.8% to $523505.0 in 2016, then surged by 603.62% to $3.7 million in 2017, then increased by 22.53% to $4.5 million in 2018.
- Per Business Quant, the three latest RLMD Short term Debt figures stand at $4.5 million (Q3 2018), $4.2 million (Q2 2018), and $4.0 million (Q1 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 4.51 Mn |
| Jun 30, 2018 | 4.19 Mn |
| Mar 31, 2018 | 3.96 Mn |
| Dec 31, 2017 | 3.68 Mn |
| Sep 30, 2017 | 2.52 Mn |
| Jun 30, 2017 | 175,853.00 |
| Mar 31, 2017 | 279,430.00 |
| Dec 31, 2016 | 523,505.00 |
| Sep 30, 2016 | 972,546.00 |
| Jun 30, 2016 | 892,503.00 |
| Mar 31, 2016 | 614,079.00 |
| Dec 31, 2015 | 1.45 Mn |
| Sep 30, 2015 | 4.71 Mn |
| Jun 30, 2015 | 14.00 Mn |
| Mar 31, 2015 | 24.47 Mn |
| Dec 31, 2014 | 26.57 Mn |
| Sep 30, 2014 | 46.82 Mn |
| Jun 30, 2014 | 25.59 Mn |